China-based InventisBio (Shanghai) has signed a 'Collaboration Agreement' with China-based Betta Pharma, it was reported on Friday.
According to the contract, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong and Taiwan) to Betta Pharma and is to co-develop this drug in China. Betta Pharma will have the exclusive commercialisation rights for the D-0316 product in the country.
The product is a third-generation EGFR-T790M tyrosine kinase inhibitor discovered and developed independently by InventisBio. It is mainly utilised for the treatment of EGFR-mutant non-small cell lung cancer. The drug is presently in phase one clinical trial in China. Betta Pharma will pay upfront and R&D milestones to InventisBio worth RMB230m. After the product is marketed commercially, Betta Pharma will pay various sales milestones and tiered royalties based on annual sales.
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
bioMérieux launches equine endocrinology tests to expand point-of-care diagnostics
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Neola Medical secures US patent for disposable lung monitoring probes
Spinogenix reports approval of 'tazbentetol' as non-proprietary name for SPG302
Polarean expands XENOVIEW 3T Coil access with Philips compatibility